Objective: We aimed to investigate the natural outcome of nonhypervascular lesions detected in the hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced MRI by performing a longitudinal study retrospectively enrolled in a nationwide manner. Methods: Between February 2008 and March 2011, 224 patients with 504 nodules that were diagnosed as nonhypervascular by imaging were recruited from institutions that participated in the present study. We examined the natural outcome of nonhypervascular lesions and evaluated the risk factors. Results: Of the 504 nodules, 173 (34.3%) showed hypervascular transformation. The overall cumulative incidence of hypervascular transformation was 14.9% at 12 months and 45.8% at 24 months. Multivariate analysis using the Cox regression model revealed previous treatment history for hepatocellular carcinoma (HCC; relative risk = 1.498; p = 0.036, 95% CI 1.03-2.19) and hyperintensity on T2-weighted images (relative risk = 1.724; p = 0.015, 95% CI 1.11-2.67) were identified as independent factors for hypervascular transformation. Conclusions: Patients who have a previous treatment history for HCC and with hypointense nodules showing hyperintensity on T2-weighted images need careful follow-up because of the high incidence of hypervascular transformation.

Keywords:
Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid, Enhanced MRI, Hepatocellular carcinoma, Hypervascular transformation
1.
Kudo M: Early hepatocellular carcinoma: definition and diagnosis. Liver Cancer 2013;2:69-72.
2.
Lee JM, Yoon JH, Joo I, Woo HS: Rencet advances in CT and MR imaging for evaluation of hepatocellular carcinoma. Liver Cancer 2012;1:22-40.
3.
Joo I, Choi BI: New paradigm for management of hepatocellular carcinoma by imaging. Liver Cancer 2012;1:94-109.
4.
Shinmura R, Matsui O, Kadoya M, Kobayashi S, Terayama N, Sanada J, Demachi H, Gabata T: Detection of hypervascular malignant foci in borderline lesions of hepatocellular carcinoma: comparison of dynamic multi-detector row CT, dynamic MR imaging and superparamagnetic iron oxide-enhanced MR imaging. Eur Radiol 2008;18:1918-1924.
5.
Hayashi M, Matsui O, Ueda K, Kawamori Y, Gabata T, Kadoya M: Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology 2002;225:143-149.
6.
Matsui O, Kadoya M, Suzuki M, Inoue K, Itoh H, Ida M, Takashima T: Work in progress: dynamic sequential computed tomography during arterial portography in the detection of hepatic neoplasms. Radiology 1983;146:721-727.
7.
Matsui O, Kadoya M, Kameyama T, Yoshikawa J, Takashima T, Nakanuma Y, Unoura M, Kobayashi K, Izumi R, Ida M, et al: Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology 1991;178:493-497.
8.
Ueda K, Matsui O, Kawamori Y, Nakanuma Y, Kadoya M, Yoshikawa J, Gabata T, Nonomura A, Takashima T: Hypervascular hepatocellular carcinoma: evaluation of hemodynamics with dynamic CT during hepatic arteriography. Radiology 1998;206:161-166.
9.
Hayashi M, Matsui O, Ueda K, Kawamori Y, Kadoya M, Yoshikawa J, Gabata T, Takashima T, Nonomura A, Nakanuma Y: Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis: evaluation by CT during intraarterial injection of contrast medium. AJR Am J Roentgenol 1999;172:969-976.
10.
Inoue E, Fujita M, Hosomi N, Sawai Y, Hashimoto T, Kuroda C, Nakano H, Sasaki Y, Ishiguro S: Double phase CT arteriography of the whole liver in the evaluation of hepatic tumors. J Comput Assist Tomogr 1998;22:64-68.
11.
Murakami T, Takamura M, Kim T, Hori M, Federle MP, Onishi H, Tomoda K, Nakamura H: Double phase CT during hepatic arteriography for diagnosis of hepatocellular carcinoma. Eur J Radiol 2005;54:246-252.
12.
Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M, Rodes J: Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference - European Association for the Study of the Liver. J Hepatol 2001;35:421-430.
13.
Huppertz A, Balzer T, Blakeborough A, Breuer J, Giovagnoni A, Heinz-Peer G, Laniado M, Manfredi RM, Mathieu DG, Mueller D, et al: Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004;230:266-275.
14.
Halavaara J, Breuer J, Ayuso C, Balzer T, Bellin MF, Blomqvist L, Carter R, Grazioli L, Hammerstingl R, Huppertz A, et al: Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT - a multicenter trial. J Comput Assist Tomogr 2006;30:345-354.
15.
Kim YK, Kim CS, Han YM, Kwak HS, Jin GY, Hwang SB, Chung GH, Lee SY, Yu HC: Detection of hepatocellular carcinoma: gadoxetic acid-enhanced 3-dimensional magnetic resonance imaging versus multi-detector row computed tomography. J Comput Assist Tomogr 2009;33:844-850.
16.
Kim SH, Lee J, Kim MJ, Jeon YH, Park Y, Choi D, Lee WJ, Lim HK: Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol 2009;192:1675-1681.
17.
Inoue T, Kudo M, Komuta M, Hayaishi S, Ueda T, Takita M, Kitai S, Hatanaka K, Yada N, Hagiwara S, et al: Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT. J Gastroenterol 2012;47:1036-1047.
18.
Tanimoto A, Lee JM, Murakami T, Huppertz A, Kudo M, Grazioli L: Consensus report of the 2nd International Forum for Liver MRI. Eur Radiol 2009;19(suppl 5):S975-S989.
19.
Kogita S, Imai Y, Okada M, Kim T, Onishi H, Takamura M, Fukuda K, Igura T, Sawai Y, Morimoto O, et al: Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol 2010;20:2405-2413.
20.
Kitao A, Zen Y, Matsui O, Gabata T, Kobayashi S, Koda W, Kozaka K, Yoneda N, Yamashita T, Kaneko S, et al: Hepatocellular carcinoma: signal intensity at gadoxetic acid- enhanced MR imaging - correlation with molecular transporters and histopathologic features. Radiology 2010;256:817-826.
21.
Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Okazaki N, Takayasu K, Kosuge T, Motoo Y, Yamazaki S, Hasegawa H: Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 1990;336:1150-1153.
22.
Kumada T, Toyoda H, Tada T, Sone Y, Fujimori M, Ogawa S, Ishikawa T: Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI. AJR Am J Roentgenol 2011;197:58-63.
23.
Akai H, Matsuda I, Kiryu S, Tajima T, Takao H, Watanabe Y, Imamura H, Kokudo N, Akahane M, Ohtomo K: Fate of hypointense lesions on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Eur J Radiol 2012;81:2973-2977.
24.
Motosugi U, Ichikawa T, Sano K, Sou H, Onohara K, Muhi A, Amemiya F, Enomoto N, Matsuda M, Fujii H, et al: Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease. J Magn Reson Imaging 2011;34:88-94.
25.
Takayama Y, Nishie A, Nakayama T, Asayama Y, Ishigami K, Kakihara D, Ushijima Y, Fujita N, Hirakawa M, Honda H: Hypovascular hepatic nodule showing hypointensity in the hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with chronic liver disease: prediction of malignant transformation. Eur J Radiol 2012;81:3072-3078.
26.
Kobayashi S, Matsui O, Gabata T, Koda W, Minami T, Ryu Y, Kozaka K, Kitao A: Relationship between signal intensity on hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced MR imaging and prognosis of borderline lesions of hepatocellular carcinoma. Eur J Radiol 2012;81:3002-3009.
27.
Hyodo T, Murakami T, Imai Y, Okada M, Hori M, Kagawa Y, Kogita S, Kumano S, Kudo M, Mochizuki T: Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma. Radiology 2013;266:480-490.
28.
Higaki A, Ito K, Tamada T, Teruki S, Yamamoto A, Higashi H, Kanki A, Sato T, Noda Y: High-risk nodules detected in the hepatobiliary phase of Gd-EOB-DTPA-enhanced MR imaging in cirrhosis or chronic hepatitis: incidence and predictive factors for hypervascular transformation, preliminary results. J Magn Reson Imaging 2013;37:1377-1383.
29.
Takechi M, Tsuda T, Yoshioka S, Murata S, Tanaka H, Hirooka M, Mochizuki T: Risk of hypervascularization in small hypovascular hepatic nodules showing hypointense in the hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with chronic liver disease. Jpn J Radiol 2012;30:743-751.
30.
Sano K, Ichikawa T, Motosugi U, Sou H, Muhi AM, Matsuda M, Nakano M, Sakamoto M, Nakazawa T, Asakawa M, et al: Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology 2011;261:834-844.
31.
Shiina S, Tateishi R, Arano T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Sato T, Masuzaki R, Kondo Y, et al: Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors. Am J Gastroenterol 2012;107:569—577, quiz 578.
32.
Wood TF, Rose DM, Chung M, Allegra DP, Foshag LJ, Bilchik AJ: Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol 2000;7:593-600.
33.
Cho YK, Rhim H, Noh S: Radiofrequency ablation versus surgical resection as primary treatment of hepatocellular carcinoma meeting the Milan criteria: a systematic review. J Gastroenterol Hepatol 2011;26:1354-1360.
34.
Nishida N, Goel A: Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review. Curr Genomics 2011;12:130-137.
35.
Nishida N, Kudo M, Nagasaka T, Ikai I, Goel A: Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Hepatology 2012;56:994-1003.
36.
Nishida N, Kudo M: Recent advancements in comprehensive genetic analyses for human hepatocellular carcinoma. Oncology 2013;84(suppl 1):93-97.
37.
Ohtomo K, Baron RL, Dodd GD 3rd, Federle MP, Ohtomo Y, Confer SR: Confluent hepatic fibrosis in advanced cirrhosis: evaluation with MR imaging. Radiology 1993;189:871-874.
38.
Kim T, Baron RL, Nalesnik MA: Infarcted regenerative nodules in cirrhosis: CT and MR imaging findings with pathologic correlation. AJR Am J Roentgenol 2000;175:1121-1125.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.